A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-03-08
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-12 (study day 235); relationship: not assessed
moderate
assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 262); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-15 (study day 389); relationship: Y
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-26 (study day 522); relationship: not assessed
Data queries
No data queries.